跳至主要内容
临床试验/DRKS00027389
DRKS00027389招募中不适用

INvestigating SIGnificant Health TrendS in Management of Progressive Fibrosing Interstitial Lung Disease (INSIGHTS-ILD) - INSIGHTS-ILD Registry

GWT-TUD GmbH Innovationszentrum Real World Evidence0 个研究点目标入组 900 人开始时间: 2021年12月7日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
900

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 one(—)
性别
All

入选标准

  • PF-ILDs, which include all ILD groups including those with IIPs, CTD-ILD, chronic hypersensitivity pneumonitis, asbestosis, sarcoidosis, etc.
  • Age = 18 years
  • Interstitial lung disease on HRCT > 10 % of lung parenchyma
  • DLco = 80 % predicted
  • On active anti-inflammatory, immunomodulatory, and or anti-fibrotic therapy
  • Written informed consent

排除标准

  • Diagnosis of IPF
  • Concomitant participation in a controlled ILD-related clinical trial, if blinded and/or with investigational drugs

研究者

发起方
GWT-TUD GmbH Innovationszentrum Real World Evidence

相似试验